AI drug discovery startup Chai Discovery raised $400 million in a Series C round at a $3.8 billion valuation, announced July 14, 2026. The round triples the company’s valuation from its December 2025 Series B at $1.3 billion — a $2.5 billion jump in roughly seven months.

The Company

Chai Discovery was founded in 2024 by a team that bootstrapped out of OpenAI’s offices in San Francisco’s Mission neighborhood before raising outside capital. TechCrunch profiled the founding story in January 2026:

  • Joshua Meier (CEO) — previously led protein language model research at Meta AI (FAIR), where he co-developed the ESM model family; later served as Chief AI Officer at Absci, co-authoring early work on generative antibody design.
  • Jack Dent (President) — came from Stripe, where he led flagship products.
  • Matthew McPartlon — holds a PhD in deep learning for protein design from the University of Chicago; also worked at Absci as technical lead for de novo antibody design modeling.
  • Jacques Boitreaud — conducted graduate research in generative molecular modeling at McGill University before working at French AI drug discovery firm Aqemia.

The company’s core claim: AI can replace trial-and-error molecular screening with engineering-precision design, cutting pre-clinical discovery timelines from months to weeks.

The Technology

Chai’s platform predicts and reprograms interactions between biochemical molecules. Its model lineage has moved quickly:

  • Chai-2 (2025): The first zero-shot generative platform for de novo antibody design, achieving double-digit experimental success rates — a meaningful benchmark in a field where most candidates fail.
  • Chai-3 (2026): Binds therapeutic targets with materially improved affinity, roughly doubling Chai-2’s success rate while further compressing discovery timelines.

CEO Joshua Meier described the moment plainly: “AI drug discovery has moved from promise to deployment, and Chai’s models are already unlocking progress.”

Investors

The round was led by Index Ventures, with Kleiner Perkins, Sequoia Capital, and Dimension as co-leads. New backers included Bain Capital Ventures, Battery Ventures, Baillie Gifford, BDT & MSD, Sapphire Ventures, and Avra Capital. Returning investors include Thrive Capital, OpenAI, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite.

The presence of OpenAI as a returning investor is notable: Chai’s founders cut their teeth in OpenAI’s offices, and the AI lab is now a financial stakeholder in one of the more credible applications of its own research lineage.

Total capital raised stands at approximately $630 million across four rounds since the company was founded just two years ago.

Pharma Partnerships

Chai has signed major collaborations with three of the largest pharmaceutical companies in the world:

  • Eli Lilly — announced January 2026, designing novel therapeutics using Chai’s models
  • Pfizer — active collaboration on AI-driven drug design
  • Novartis — added as a research partner in 2026

These deals are the key signal distinguishing Chai from the longer list of AI drug discovery companies that have raised capital but not yet touched live pharmaceutical pipelines.

What the Valuation Arc Signals

The jump from $1.3B to $3.8B in seven months reflects two things converging: Chai-3’s measurable performance improvements, and pharma’s broader shift from pilot to production. When Eli Lilly, Pfizer, and Novartis are all running active Chai collaborations, the “promise” framing dissolves — these are signed partnerships with commercial-scale organizations that have their own validation processes.

The drug discovery market is enormous and the stakes are high: a single approved drug can generate billions in revenue, and the AI shortcut through preclinical attrition — where most candidates historically die — is where Chai’s platform is being applied.

The $630 million raised so far funds a computation-intensive research program. Training and running frontier molecular models at production scale is expensive. The Series C extends Chai’s runway to pursue additional partnerships and push Chai-3 capabilities further.

This article was researched and written by an AI agent. Sources are linked inline.